Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 92 clinical trials
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working

cytarabine
leukemia
myeloid leukemia
acute leukemia
hydroxyurea
  • 0 views
  • 25 Mar, 2022
  • 1 location
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

> Objective To study if tetrahydrouridine-decitabine (THU-DAC) with pembrolizumab is safe and effective in people with non-small cell lung cancer that cannot be removed by

measurable disease
cancer
antineoplastic
neutrophil count
pembrolizumab
  • 21 views
  • 11 Aug, 2022
  • 1 location
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

involved in this study are: Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) Decitabine, a chemotherapy drug

remission
blast cells
hla-a
gilbert's syndrome
graft versus host disease
  • 0 views
  • 16 Feb, 2022
  • 1 location
Inqovi Maintenance Therapy in Myeloid Neoplasms

care stem cell transplant. This research study involves the study drug Inqovi, which is a combination of the drugs decitabine and cedazuridine.

myelomonocytic leukemia
leukemia
chronic myelomonocytic leukemia
hla-a
cell transplantation
  • 0 views
  • 17 Oct, 2021
  • 1 location
Tegavivint for the Treatment of Relapsed or Refractory Leukemia

). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint in combination with decitabine may help control the disease.

  • 0 views
  • 26 Mar, 2022
  • 1 location
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial

decitabine, cytarabine, and aclarubicin (D-CTAG regimen) to treat older adults with newly diagnosed AML (Identifier: NCT04168138). The above agents were administered as follows: decitabine (15 mg/m2 daily

cytarabine
filgrastim
granulocyte colony stimulating factor
decitabine
  • 0 views
  • 04 Jun, 2022
  • 1 location
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study

decitabine, cytarabine, and aclarubicin (D-CTAG regimen) to treat older adults with newly diagnosed AML (Identifier: NCT04168138). The above agents were administered as follows: decitabine (15 mg/m2 daily

cytarabine
filgrastim
granulocyte colony stimulating factor
decitabine
  • 0 views
  • 17 Mar, 2022
  • 1 location
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), depending on the patient's prior induction treatment.

remission
blast cells
cytarabine
mitoxantrone
idarubicin
  • 76 views
  • 16 Feb, 2022
  • 35 locations
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features

hybridization (FISH) and next-generation sequencing (NGS), such as the combination of Venetoclax plus decitabine, and Sorafenib for patients with high (FMS)-like tyrosine kinase 3-internal tandem duplication

  • 0 views
  • 22 Nov, 2021
  • 1 location
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post

transplant conditioning
decitabine
  • 0 views
  • 27 May, 2022
  • 1 location